121 Using a scenario approach to assess for the current and future demand of immunoglobulins 46. Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on ‘off-label’ therapeutic options for systemic lupus erythe- matosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland - a consensus report. Lupus. 2012;21(4):386-401. 47. Rodriguez MM, Wagner-Weiner L. Intravenous immunoglobulin in pediatric rheumatology: when to use it and what is the evidence. Pediatr Ann. 2017;46(1):e19-e24. 48. Barut K, Sahin S, Adrovic A, Kasapcopur O. Diagnostic approach and current treatment options in childhood vasculitis. Türk Pediatri Ars¸ivi. 2015;50(4):194-205. 49. Soares MO, Welton NJ, Harrison DA, et al. Intravenous immunoglobulin for severe sepsis and septic shock: clinical effectiveness, cost-effectiveness and value of a further randomised controlled trial. Crit Care. 2014;18(6):649. 50. Nierhaus A, Berlot G, Kindgen-Milles D, Müller E, Girardis M. Best- practice IgM- and IgA-enriched immunoglobulin use in patients with sepsis. Ann Intensive Care. 2020;10(1):132. 51. Brand A, De Angelis V, Vuk T, Garraud O, Lozano M, Politis D. Review of indications for immunoglobulin (IG) use: narrowing the gap between supply and demand. Transfusi Clin Biol. 2021;28(1): 96-122. 52. Sung N, Han AR, Park CW, et al. Intravenous immunoglobulin G in women with reproductive failure: the Korean Society for Reproductive Immunology practice guidelines. Clin Exp Reprod Med. 2017; 44(1):1-7. 53. Shaulov T, Sierra S, Sylvestre C. Recurrent implantation failure in IVF: a Canadian fertility and andrology society clinical practice guideline. Reprod Biomed Online. 2020;41(5):819-833. 54. Murphy MSQ, Tinmouth A, Goldman M, et al. Trends in IVIG use at a tertiary care Canadian center and impact of provincial use mitigation strategies: 10-year retrospective study with interrupted time series analysis. Transfusion. 2019;59(6):1988-1996. 55. Barmettler S, Ong MS, Farmer JR, Choi H, Walter J. Association of Immunoglobulin Levels, infectious risk, and mortality with rituximab and Hypogammaglobulinemia. JAMA Netw Open. 2018;1(7): e184169. 56. Anwer F, Shaukat A, Zahid U, et al. Donor origin CAR T cells: graft versus malignancy effect without GVHD, a systematic review. Immu- notherapy. 2017;9:123-130. 57. Zahid U, Shaukat A, Hassan N, Anwer F. Coccidioidomycosis, immunoglobulin deficiency: safety challenges with CAR T cells therapy for relapsed lymphoma. Immunotherapy. 2017;9:1061-1066. 58. Hill JA, Boeckh M, Li D, et al. Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immuno- therapy. Blood. 2018;131(1):121-130. 59. Edington HJ, Sutton KS, Bennett C, Chandrakasan S, Sterner- Allison J, Castellino SM. Dealing with a critical national shortage- approaches to triaging immune globulin supply in pediatric hematology and oncology. Pediatr Blood Cancer. 2020;67(7):e28260.
RkJQdWJsaXNoZXIy MTk4NDMw